Navigation Links
Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial
Date:5/22/2008

LAS VEGAS, May 22 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) has entered into an agreement with Dr. H. Christopher Moore to be the sponsor and general partner of ProDerm Limited Partnership (PDLP) which will fund a minimum of $1 million and up to $10 million of the clinical development for CVBT's wound healing drug candidate.

"I am extremely impressed with CVBT's wound healing drug, which I believe has the potential to treat patients for diabetic ulcers and venous stasis leg wounds better than any of the current products on the market. The active pharmaceutical ingredient (API) is truly remarkable," said Dr. Moore.

PDLP will engage CVBT in a development agreement to conduct wound healing clinical trials. CVBT will pay a royalty to PDLP of 10% of revenues or other moneys received from the commercialization of the drug candidate up to a maximum of twenty times (20x) the funded amount of the development agreement in exchange for the intellectual property created. Daniel C. Montano, CVBT's President and CEO, has agreed to personally provide the individual partners of PDLP a "Put" to Mr. Montano for their interest in CDCP equal to 200% of their investment in PDLP less distributions paid from PDLP commencing 36 months and ending 60 months after their investment in PDLP.

"These clinical partnerships are very important to the timely development of CVBT's drug candidates. The ability to access the necessary funding for CVBT's FDA clinical trials through clinical partnerships during these uncertain times for the capital markets gives us the ability to move forward with our planned clinical development schedule," said Mr. Montano.

"CVBT now has two clinical partnerships in place supporting its trials through development agreements. The relative cost of capital and the minimal dilution to existing shareholders makes this financing vehicle an attractive alternative to selling equity and placing debt in the current capital markets environment," said Mickael A. Flaa, CFO of CVBT.

About Dr. H. Christopher Moore

Dr. H. Christopher Moore, M.D., F.A.C.S., has both a B.S. and a Medical degree from the University of Southern California. He is a Diplomate of both the American Board of Otolaryngology and the American board of Facial Plastic and Reconstructive Surgery. He has been a Professor of Surgery at the University of California, Irvine, and has been a frequent lecturer on Facial Plastic and Reconstructive Surgery throughout the U.S. Currently, Dr. Moore practices in Fullerton, CA.

Dr. Moore has independently owned and operated a successful outpatient surgery center in Fullerton. At this time, he is invested as a limited partner and serves on the Board of Directors of a large multi-specialty surgery center in Fullerton. He was also a founding member of Cryoport, Inc., a company that developed, manufactures and markets an ultra low temperature shipping device. Dr. Moore remains involved as a major shareholder in this company.

About CardioVascular BioTherapeutics, Inc.

CVBT is a biopharmaceutical company developing drug candidates formulated with human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetes and in patients suffering from peripheral artery disease of the legs. An additional proof-of-concept study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information please visit http://www.cvbt.com.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contact:

Allison Caplan

CardioVascular BioTherapeutics, Inc.

(702) 839-7235

acaplan@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
3. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
4. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
5. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
6. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
7. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
Breaking Medicine News(10 mins):